Ultrasound IDs patients at higher risk for stroke
Using transcranial Doppler ultrasound to detect asymptomatic cerebral emboli can identify patients who are at a higher risk of stroke and transient ischemic attack as well as those with a low absolute stroke risk, according to an international study.
Using transcranial Doppler ultrasound to detect asymptomatic cerebral emboli can identify patients who are at a higher risk of stroke and transient ischemic attack as well as those with a low absolute stroke risk, according to an international study.
The technique might also be useful in selecting patients with asymptomatic carotid stenosis who are likely to benefit from endarterectomy.
Embolic signs-short duration, high-energy signals-were present in 77 of 467 patients at baseline. The hazard ratio for the risk of ipsilateral stroke and transient ischemic attack from baseline to two years in patients with embolic signals compared with those without was 2.54. The hazard ratio for ipsilateral stroke alone was 5.57 (Lancet DOI:10.1016/S1474-4422(10)70120-4).
Absolute annual risk of ipsilateral stroke or a transient ischemic attack between baseline and two years was 7.13% in patients with embolic signals and 3.04% in those without. The absolute annual risk of ipsilateral stroke alone was 3.62% in patients with embolic signals and 0.7% in those without.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
August 2nd 2025In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
August 2nd 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.
